Historically, the bio/pharmaceutical industry has been hesitant to adopt social media strategies, mainly due to the lack of regulatory guidance. The June 2014 FDA draft guidance on the Internet and social media has clarified some questions regarding what is considered to be appropriate messaging on social media sites, including patient/physician forums, Facebook, YouTube and Twitter (to name a few). Though the guidance is new, it has definitely helped to interpret regulatory stances on the topic. I had the pleasure of discussing the social media draft guidance with Howard Dorfman, Vice President and General Counsel at Ferring Pharmaceuticals. He was able to shed some light on what the FDA guidance really means for industry, including how industry has and will continue to change, industry strategies, what is still unclear and what SOPs might be put in place to better utilize the social media world.